Medicare AdvantageCoverageMedium impact
Varicose Vein Treatments - Medicare Advantage (Revised)
Humana·Vascular Surgery, General Surgery·Medicare Advantage
Effective date
Apr 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated their varicose vein treatment policy, effective April 1, 2026. The policy establishes medical necessity criteria for chemical adhesive embolization and mechanochemical ablation procedures in jurisdictions without existing CMS guidance, using LCD L39121 criteria as the standard.
Action Required
Before April 1, 2026: Billing team must review LCD L39121 criteria for chemical adhesive embolization (CPT 36482, 36483) and mechanochemical ablation (CPT 36473, 36474) procedures. Update prior authorization workflows to ensure medical necessity documentation aligns with these criteria for Humana Medicare Advantage members in jurisdictions J5, J8, J15, JE, and JF. Verify patient eligibility and geographic coverage areas before scheduling these procedures.